Overview

A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

Status:
Active, not recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.
Phase:
Phase 2
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.